Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 5 de 5
1.
Rev. bras. cir. cardiovasc ; 37(5): 744-753, Sept.-Oct. 2022. tab
Article En | LILACS-Express | LILACS | ID: biblio-1407302

Abstract There remains a significant paucity of information evaluating the effect of glycated HbA1c levels and its theorized effect on mortality and morbidity rates following cardiac surgery. Diabetes is a very common comorbidity in patients undergoing open heart surgery, as there is a shift in patient characteristics and greater risk. Currently, there is no clear consensus that an increase in HbA1c level is associated with increased perioperative mortality rate. However, the reported literature is more commonly able to demonstrate that elevated HbA1c levels is associated with increased rates of wound infection, cardiovascular events and renal failure, and thus, higher post-operative morbidities. This review aims to examine and synthesis the evidence behind each of the morbidities and mortalities associated with open heart surgery and the impact of high HbA1c on the reported outcomes.

2.
J Card Surg ; 37(12): 4267-4268, 2022 Dec.
Article En | MEDLINE | ID: mdl-36087006

BACKGROUND: Acute type A aortic dissection (ATAAD) is a life-threatening medical condition requiring urgent surgical attention. It is estimated that 50% of ATAAD die within 24 h of onset, with the mortality rate is increasing by 1%-2% every additional hour without prompt intervention. A variety of ATAAD surgical repair techniques exist which has sparked controversy within the literature, with the main two strategies being proximal aortic replacement (PAR) and total arch replacement (TAR). Nevertheless, the question of which of these two strategies if the more optimal is still debatable. AIMS: This commentary aims to discuss the recent study by Sa and colleagues which presents a pooled analysis of Kaplan-Meier-derived individual patient data from studies with follow-up comparing aggressive (TAR) and conservative (PAR) approaches to manage ATAAD patients. METHODS: A comprehensive literature search was performed using multiple electronic databases including PubMed, Ovid, Google Scholar, EMBASE, and Scopus to collate the relevant research evidence. RESULTS: The more aggressive TAR approach for treating ATAAD seems to yield more favorable results including more optimal long-term survival as well as a lower need for reoperation. The frozen elephant trunk (FET) technique can be considered the mainstay TAR technique. CONCLUSION: It is valid to conclude that TAR with FET is the superior strategy for managing ATAAD patients.


Aortic Aneurysm, Thoracic , Aortic Dissection , Blood Vessel Prosthesis Implantation , Humans , Blood Vessel Prosthesis Implantation/methods , Treatment Outcome , Retrospective Studies , Aortic Dissection/surgery , Aorta/surgery , Aortic Aneurysm, Thoracic/surgery , Aorta, Thoracic/surgery
3.
Braz J Cardiovasc Surg ; 37(5): 744-753, 2022 10 08.
Article En | MEDLINE | ID: mdl-33577257

There remains a significant paucity of information evaluating the effect of glycated HbA1c levels and its theorized effect on mortality and morbidity rates following cardiac surgery. Diabetes is a very common comorbidity in patients undergoing open heart surgery, as there is a shift in patient characteristics and greater risk. Currently, there is no clear consensus that an increase in HbA1c level is associated with increased perioperative mortality rate. However, the reported literature is more commonly able to demonstrate that elevated HbA1c levels is associated with increased rates of wound infection, cardiovascular events and renal failure, and thus, higher post-operative morbidities. This review aims to examine and synthesis the evidence behind each of the morbidities and mortalities associated with open heart surgery and the impact of high HbA1c on the reported outcomes.


Cardiac Surgical Procedures , Diabetes Mellitus , Humans , Glycated Hemoglobin/analysis , Cardiac Surgical Procedures/adverse effects , Morbidity , Risk Factors
4.
Cardiol Young ; 31(12): 1929-1937, 2021 Dec.
Article En | MEDLINE | ID: mdl-33818355

BACKGROUND: Vocal cord palsy is one of the recognised complications of complex cardiac surgery in the paediatric population. While there is an abundance of literature highlighting the presence of this complication, there is a scarcity of research focusing on the pathophysiology, presentation, diagnosis, and treatment options available for children affected by vocal cord palsy. MATERIALS AND METHODS: Electronic searches were conducted using the search terms: "Vocal Cord Palsy," "VCP," "Vocal Cord Injury," "Paediatric Heart Surgery," "Congenital Heart Surgery," "Pediatric Heart Surgery," "Vocal Fold Movement Impairment," "VFMI," "Vocal Fold Palsy," "PDA Ligation." The inclusion criteria were any articles discussing the outcomes of vocal cord palsy following paediatric cardiac surgery. RESULTS: The two main populations affected by vocal cord palsy are children undergoing aortic arch surgery or those undergoing PDA ligation. There is paucity of prospective follow-up studies; it is therefore difficult to reliably assess the current approaches and the long-term implications of management options. CONCLUSION: Vocal cord palsy can be a devastating complication following cardiac surgery, which if left untreated, could potentially result in debilitation of quality of life and in severe circumstances could even lead to death. Currently, there is not enough high-quality evidence in the literature to aid recognition, diagnosis, and management leaving clinicians to extrapolate evidence from adult studies to make clinical judgements. Future research with a focus on the paediatric perspective is necessary in providing evidence for good standards of care.


Cardiac Surgical Procedures , Vocal Cord Paralysis , Adult , Cardiac Surgical Procedures/adverse effects , Child , Humans , Postoperative Complications , Prospective Studies , Quality of Life , Vocal Cord Paralysis/diagnosis , Vocal Cord Paralysis/etiology
5.
Expert Opin Drug Discov ; 16(2): 115-117, 2021 02.
Article En | MEDLINE | ID: mdl-32915657

Introduction: The COVID-19 pandemic has catalyzed the production of potential antivirals and vaccines from research organizations across the globe. The initial step for all drug discovery models is the identification of suitable targets. One approach organizations may take to tackle this involves issuing raw data publicly for collaboration with other organizations in order to spark discussion, collectively experiment and stay up to date with advances in scientific knowledge. Areas covered: Numerous organizations have released genomic data, amongst other tools, for the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and this has led to the development of growing datasets of knowledge for continued collaboration amongst different scientific communities. A different technique employs a more closed, market-driven method in order to stay ahead financially in the race for developing a suitable antiviral or vaccine. The latter allows sustained motivation for company ambitions and progress has been made toward clinical trials for potential drugs. Expert opinion: A case can be made for both open and closed drug discovery models; however, due to the rapidly evolving nature of this deadly virus, organizations should collate their research and support one another to ensure satisfactory treatment can be approved in a timely manner.


Antiviral Agents/pharmacology , COVID-19 Drug Treatment , Drug Discovery/organization & administration , SARS-CoV-2 , Viral Vaccines/pharmacology , COVID-19/epidemiology , COVID-19/prevention & control , Clinical Trials as Topic , Drug Discovery/economics , Drug Discovery/methods , Humans , International Cooperation , SARS-CoV-2/drug effects , SARS-CoV-2/genetics
...